The Joint reacquires Texas rights for USD 8.00 million: what it means for The Joint stock

Published on 10/06/2026 at 08:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Texas includes 141 clinics and sellers retain eight under the October 1 deal. USD 102.4 million values The Joint stock as of October 5, 2026.

JYNT, US47973J1025, Illustration mit AI erstellt.

The Joint Corp. (ISIN US47973J1025) agreed to reacquire Texas regional development rights for USD 8.00 million in cash on October 1, 2026, according to StockTitan. The deal gives the company more control over a Texas region that included 141 franchised clinics on that date.

What the Texas deal means

The purchase price is USD 8.00 million at execution, with up to USD 2.00 million in additional consideration tied to gross sales metrics during the two annual periods beginning September 1, 2026, StockTitan reported from the filing. The sellers will continue to franchise eight clinics through affiliates, leaving the transaction focused on regional development rights rather than a full exit from Texas.

The financial trade-off is visible in the scale of the purchase. The maximum contingent payment equals 25.00 percent of the initial USD 8.00 million cash outlay, although the additional amount depends on future sales performance.

Revenue growth meets a loss

The Joint reported USD 15.18 million of revenue for the second quarter of 2026, compared with USD 13.27 million in the second quarter of 2025, an increase of 14.39 percent, according to Markets Insider. The same report said quarterly revenue exceeded the USD 14.57 million consensus estimate, while earnings per share came in at USD 0.05.

That comparison places the Texas transaction against a business that is still expanding its revenue base but must fund regional control with cash. The company reported USD 23.00 million of cash at June 30, 2026, while the Texas payment represents 34.78 percent of that balance.

Roth MKM keeps a USD 12 target

Roth MKM analyst George Kelly reiterated a Buy rating and set a USD 12.00 price target on October 2, 2026, Markets Insider reported. The article also listed a Moderate Buy consensus and an average target of USD 10.50, giving investors a separate benchmark for the Texas investment decision.

Nasdaq quote and market value

JYNT was last at USD 7.18 on the Nasdaq on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 102.4 million. The company operates in healthcare through corporate-owned clinics and franchised chiropractic facilities.